Fluticasone propionate hfa clinical efficacy
Pro Research Analysisby 
Searched over 200M research papers
Clinical Efficacy of Fluticasone Propionate HFA in Asthma Management
Fluticasone Propionate HFA vs. CFC Formulations in Asthma
Multiple studies have shown that fluticasone propionate delivered via hydrofluoroalkane (HFA) 134a pressurized metered dose inhalers (pMDIs) is clinically equivalent in efficacy and safety to the older chlorofluorocarbon (CFC) formulations for patients with mild, moderate, and severe asthma. Improvements in lung function, such as morning peak expiratory flow (PEF), were similar between HFA and CFC groups, with increases maintained over both short-term (4 weeks) and long-term (12 months) treatment periods. Both formulations also showed comparable improvements in other asthma control measures, including symptom scores and clinic lung function tests, with no significant differences in adverse events or serum cortisol levels across age groups, including children and adults Perruchoud2000Tonnel2000Ayres2000+1 MORE.
Efficacy in Combination Therapy: Fluticasone Propionate/Salmeterol HFA
Studies comparing fluticasone propionate/salmeterol HFA pMDI to dry powder inhaler (DPI) formulations found that the HFA pMDI at a lower corticosteroid dose provided non-inferior asthma control. Both delivery methods led to significant improvements in lung function, reduced asthma symptoms, fewer exacerbations, and decreased use of rescue medication. Notably, the HFA pMDI formulation was associated with a lower incidence of local side effects, such as hoarseness, compared to the DPI Kupczyk2020Kupczyk2020. Additionally, combination therapy with fluticasone propionate/salmeterol HFA resulted in greater improvements in lung function and asthma control compared to either component alone, with a safety profile similar to monotherapy .
Fluticasone Propionate HFA Compared to Other Inhaled Corticosteroids
When compared to HFA-beclomethasone dipropionate (HFA-BDP), fluticasone propionate HFA demonstrated similar efficacy in improving asthma control, as measured by increases in morning PEF and reductions in asthma symptoms. Both treatments were well tolerated, with no significant differences in adverse events or effects on cortisol levels Aubier2001Aubier2001.
Efficacy in Reducing Airway Hyperresponsiveness
Fluticasone propionate HFA was found to be equivalent to the Diskhaler (a dry powder inhaler) in reducing airway hyperresponsiveness, as measured by methacholine challenge, and in improving lung function in patients with mild asthma. Both delivery methods were well tolerated and did not significantly affect serum cortisol levels .
Conclusion
Fluticasone propionate HFA pMDI is as effective and safe as CFC-based and dry powder inhaler formulations for the treatment of asthma across a range of severities and age groups. It provides significant improvements in lung function and asthma control, both as monotherapy and in combination with salmeterol, with a favorable safety profile and the added benefit of being a non-ozone depleting option Perruchoud2000Tonnel2000Ayres2000+4 MORE.
Sources and full results
Most relevant research papers on this topic